Skip to main content

ICH 5QC Stability testing of biotechnological/biological products (CPMP/ICH/138/95)

ICH Topic Q5C, as outlined in document CPMP/ICH/138/95, addresses the stability testing of biotechnological and biological products. This guideline provides a framework for assessing the stability of these products over time, ensuring that they maintain their quality, safety, and efficacy throughout their shelf life. Below is an elaboration of ICH Q5C:


1. Purpose of ICH Q5C:

The primary purpose of ICH Q5C is to establish principles and guidelines for conducting stability testing of biotechnological and biological products. The goal is to provide evidence that these products remain safe and effective during their intended shelf life.

2. Types of Products Covered:

ICH Q5C applies to a wide range of biotechnological and biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and other biopharmaceuticals.

3. Stability Study Design:

The guideline outlines the design of stability studies, including the selection of relevant storage conditions, time points for sampling, and the duration of the study. Stability studies should be conducted under controlled conditions that mimic the product's anticipated storage conditions.

4. Stability Testing Parameters:

Various stability testing parameters should be evaluated, including but not limited to physical and chemical attributes, biological activity, purity, impurities, and degradation products. The choice of parameters depends on the specific product characteristics.

5. Stress Testing:

Stress testing involves exposing the product to extreme conditions (e.g., high temperature, humidity, light) to accelerate degradation. It helps to identify potential degradation pathways and degradation products.

6. Specification Setting:

Based on stability data, specifications are established for the product. These specifications define acceptable ranges for various attributes to ensure product quality. Any changes in specifications must be justified and supported by data.

7. Real-Time and Accelerated Studies:

Stability studies typically include real-time and accelerated testing. Real-time studies are conducted at the intended storage conditions over the expected shelf life, while accelerated studies are conducted under more severe conditions to predict long-term stability.

8. Bracketing and Matrixing:

Bracketing and matrixing are statistical approaches to reduce the number of samples in stability testing, especially for products with similar characteristics. These approaches allow for efficient data collection while maintaining statistical rigor.

9. Data Analysis and Reporting:

Robust data analysis is essential, and stability results should be reported in a clear and concise manner. Manufacturers must provide evidence that the product meets its defined specifications and remains stable over time.

10. Regulatory Submission:

- Stability data are a critical part of regulatory submissions for marketing authorization. Manufacturers should include detailed stability study reports and data to support the product's shelf life claims.

11. Post-Approval Changes:

- Manufacturers should consider stability testing when making post-approval changes to the product, such as formulation modifications or changes in manufacturing processes. Stability data may be required to support these changes.

12. Storage and Labeling:

- Stability data also inform product storage conditions and labeling instructions. The recommended storage conditions on product labels should be based on stability data.


In summary, ICH Q5C provides comprehensive guidance on the stability testing of biotechnological and biological products. This guideline is essential to ensure that these products maintain their quality, safety, and efficacy throughout their shelf life. Compliance with these guidelines is crucial for obtaining regulatory approval and for post-approval product maintenance

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more